FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma

"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."01/02/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news